JP2017128614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017128614A5 JP2017128614A5 JP2017091305A JP2017091305A JP2017128614A5 JP 2017128614 A5 JP2017128614 A5 JP 2017128614A5 JP 2017091305 A JP2017091305 A JP 2017091305A JP 2017091305 A JP2017091305 A JP 2017091305A JP 2017128614 A5 JP2017128614 A5 JP 2017128614A5
- Authority
- JP
- Japan
- Prior art keywords
- release layer
- pharmaceutical composition
- dibutyl sebacate
- magnesium stearate
- sustained release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 14
- PYGXAGIECVVIOZ-UHFFFAOYSA-N dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 10
- 229940031954 dibutyl sebacate Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000003111 delayed Effects 0.000 claims 7
- 235000019359 magnesium stearate Nutrition 0.000 claims 7
- 230000002459 sustained Effects 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 239000001856 Ethyl cellulose Substances 0.000 claims 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 5
- 229940117841 Methacrylic Acid Copolymer Drugs 0.000 claims 5
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims 5
- 229920001249 ethyl cellulose Polymers 0.000 claims 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 5
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 5
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 5
- 229940068968 Polysorbate 80 Drugs 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Adhd patch Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 3
- 229940057948 Magnesium stearate Drugs 0.000 claims 3
- 229960001344 Methylphenidate Drugs 0.000 claims 3
- 229960004667 ethyl cellulose Drugs 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 239000002269 analeptic agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (5)
- 中枢神経系刺激薬の投与に応答性の障害または状態を有する被験体の状態を処置するための、単回遅延放出投薬量で経口投与するための薬学的組成物であって、該組成物は、
治療量のメチルフェニデートまたはその薬学的な塩と少なくとも1種類の薬学的に許容され得る賦形剤とを含むコア;
該コアをコーティングしている持続放出層;および
該持続放出層をコーティングしている遅延放出層
を含み、
ここで、該持続放出層は、エチルセルロース、ヒドロキシプロピルセルロース、セバシン酸ジブチルおよびステアリン酸マグネシウムを含み、そしてここで、該遅延放出層は、メタクリル酸コポリマーB型、セバシン酸ジブチル、モノ−およびジ−グリセリドを含む、
薬学的組成物。 - 請求項1に記載の薬学的組成物であって、ここで、前記持続放出層が、エチルセルロース、ヒドロキシプロピルセルロース、セバシン酸ジブチルおよびステアリン酸マグネシウムからなり、そして前記遅延放出層が、メタクリル酸コポリマーB型、モノ−およびジ−グリセリド、セバシン酸ジブチルおよびポリソルベート80からなり、ここで、ステアリン酸マグネシウムが、該組成物の合計の5.39重量%で存在する、薬学的組成物。
- 請求項1に記載の薬学的組成物であって、ここで、前記持続放出層が、エチルセルロース、ヒドロキシプロピルセルロース、セバシン酸ジブチルおよびステアリン酸マグネシウムからなり、そして前記遅延放出層が、メタクリル酸コポリマーB型、モノ−およびジ−グリセリド、セバシン酸ジブチルおよびポリソルベート80からなり、ここで、ステアリン酸マグネシウムが、該組成物の合計の6.25重量%で存在する、薬学的組成物。
- 請求項2に記載の薬学的組成物であって、該組成物は、
13.54%のメチルフェニデート、48.00%の微晶質セルロースからなるコア、
7.56%のエチルセルロース、1.89%のヒドロキシプロピルセルロース、0.55%のセバシン酸ジブチルおよび5.39%のステアリン酸マグネシウムからなる持続放出層、および
18.60%のメタクリル酸コポリマーB型、1.87%のモノ−およびジ−グリセリド、1.87%のセバシン酸ジブチルおよび0.74%のポリソルベート80からなる遅延放出層
からなり、
ここで、該パーセンテージが該組成物全体の重量%である、
薬学的組成物。 - 請求項3に記載の薬学的組成物であって、該組成物は、
15.28%のメチルフェニデート、54.16%の微晶質セルロースからなるコア、
5.78%のエチルセルロース、1.45%のヒドロキシプロピルセルロース、0.42%のセバシン酸ジブチルおよび6.25%のステアリン酸マグネシウムからなる持続放出層、および
13.43%のメタクリル酸コポリマーB型、1.35%のモノ−およびジ−グリセリド、1.35%のセバシン酸ジブチルおよび0.53%のポリソルベート80からなる遅延放出層
からなり、
ここで、該パーセンテージが該組成物全体の重量%である、
薬学的組成物。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161466684P | 2011-03-23 | 2011-03-23 | |
US61/466,684 | 2011-03-23 | ||
US201161561763P | 2011-11-18 | 2011-11-18 | |
US61/561,763 | 2011-11-18 | ||
US201261591129P | 2012-01-26 | 2012-01-26 | |
US61/591,129 | 2012-01-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016058474A Division JP2016117767A (ja) | 2011-03-23 | 2016-03-23 | 注意欠陥障害の処置のための方法および組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017128614A JP2017128614A (ja) | 2017-07-27 |
JP2017128614A5 true JP2017128614A5 (ja) | 2018-02-08 |
JP6325148B2 JP6325148B2 (ja) | 2018-05-16 |
Family
ID=46879766
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014501292A Active JP6043785B2 (ja) | 2011-03-23 | 2012-03-23 | 注意欠陥障害の処置のための方法および組成物 |
JP2016058474A Withdrawn JP2016117767A (ja) | 2011-03-23 | 2016-03-23 | 注意欠陥障害の処置のための方法および組成物 |
JP2017091305A Active JP6325148B2 (ja) | 2011-03-23 | 2017-05-01 | 注意欠陥障害の処置のための方法および組成物 |
JP2018179001A Withdrawn JP2018197276A (ja) | 2011-03-23 | 2018-09-25 | 注意欠陥障害の処置のための方法および組成物 |
JP2020035076A Withdrawn JP2020079322A (ja) | 2011-03-23 | 2020-03-02 | 注意欠陥障害の処置のための方法および組成物 |
JP2022030878A Withdrawn JP2022066315A (ja) | 2011-03-23 | 2022-03-01 | 注意欠陥障害の処置のための方法および組成物 |
JP2023223409A Pending JP2024019726A (ja) | 2011-03-23 | 2023-12-28 | 注意欠陥障害の処置のための方法および組成物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014501292A Active JP6043785B2 (ja) | 2011-03-23 | 2012-03-23 | 注意欠陥障害の処置のための方法および組成物 |
JP2016058474A Withdrawn JP2016117767A (ja) | 2011-03-23 | 2016-03-23 | 注意欠陥障害の処置のための方法および組成物 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018179001A Withdrawn JP2018197276A (ja) | 2011-03-23 | 2018-09-25 | 注意欠陥障害の処置のための方法および組成物 |
JP2020035076A Withdrawn JP2020079322A (ja) | 2011-03-23 | 2020-03-02 | 注意欠陥障害の処置のための方法および組成物 |
JP2022030878A Withdrawn JP2022066315A (ja) | 2011-03-23 | 2022-03-01 | 注意欠陥障害の処置のための方法および組成物 |
JP2023223409A Pending JP2024019726A (ja) | 2011-03-23 | 2023-12-28 | 注意欠陥障害の処置のための方法および組成物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9028868B2 (ja) |
EP (4) | EP2688557B1 (ja) |
JP (7) | JP6043785B2 (ja) |
KR (2) | KR101834033B1 (ja) |
CN (2) | CN110151731A (ja) |
AU (3) | AU2012230733B2 (ja) |
BR (1) | BR112013024401B1 (ja) |
CA (1) | CA2830788C (ja) |
DK (3) | DK2688557T3 (ja) |
ES (3) | ES2644942T3 (ja) |
MX (3) | MX357551B (ja) |
PT (3) | PT3272342T (ja) |
SG (2) | SG193587A1 (ja) |
WO (1) | WO2012129551A1 (ja) |
ZA (1) | ZA201307649B (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11241391B2 (en) * | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) * | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) * | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) * | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) * | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
CA3018328A1 (en) | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
IL255343B2 (en) * | 2015-05-04 | 2024-10-01 | Confluence Pharmaceuticals Llc | Essay formulations of acamprosate |
ES2944568T3 (es) * | 2015-07-17 | 2023-06-22 | Be Pharbel Mfg | Micropartículas multicapa de liberación de compuestos farmacéuticamente activos en forma de dosificación líquida |
US10383825B2 (en) | 2015-08-13 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | Calcium alginate dosage formulations, and methods of making and using thereof |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
WO2017173068A1 (en) * | 2016-03-30 | 2017-10-05 | University Of Maryland, Baltimore | Microparticulate system for colonic drug delivery |
EP3439657A4 (en) * | 2016-05-26 | 2019-12-18 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISTURBANCES USING PIPRADROL |
EP3481381A4 (en) * | 2016-07-06 | 2020-01-01 | Durect Corporation | ORAL PHARMACEUTICAL FORM WITH ACTIVE COMPOSITION, BARRIER AND ACTIVE LAYER |
US9931303B1 (en) | 2017-02-06 | 2018-04-03 | Alcobra Ltd. | Abuse deterrent formulations of amphetamine |
US20180256515A1 (en) * | 2017-03-10 | 2018-09-13 | Adare Pharmaceuticals, Inc. | Oral amphetamine composition |
EP3616696A4 (en) | 2017-04-28 | 2021-01-27 | Astellas Pharma Inc. | PHARMACEUTICAL COMPOSITION CONTAINING ENZALUTAMIDE WHICH MAY BE ADMINISTERED ORALLY |
KR20200005576A (ko) | 2017-05-17 | 2020-01-15 | 컨플루언스 파마슈티컬스, 엘엘씨 | 호모타우린 및 이의 염의 제형 |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
CN108653243B (zh) * | 2018-03-30 | 2019-03-22 | 江苏南农高科动物药业有限公司 | 一种缓释替米考星微囊粉的制备方法 |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
EP3662900A1 (en) * | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Colonic drug delivery formulation |
BR112021014593A2 (pt) * | 2019-01-25 | 2021-10-05 | Ironshore Pharmaceuticals & Development, Inc. | Composições de metilfenidato para tratamento de transtorno de déficit de atenção e hiperatividade |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8322007D0 (en) | 1983-08-16 | 1983-09-21 | Wellcome Found | Pharmaceutical delivery system |
US4904476A (en) | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
RU2104084C1 (ru) | 1989-02-16 | 1998-02-10 | Бритиш Технолоджи Груп Лимитед | Капсула дозируемого выброса |
JP2558396B2 (ja) | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
JP2916978B2 (ja) | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
US5658590A (en) | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
IT1276689B1 (it) | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
GB9514451D0 (en) | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US5922736A (en) | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US6355656B1 (en) | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
MX9805870A (ja) | 1996-01-22 | 1999-01-31 | ||
EP0879228B1 (en) | 1996-02-02 | 2002-10-30 | Medeva Europe Limited | Process for the preparation of d-threo-(r,r)-methyl phenidate and recycling of undesired enantiomers by epimerisation |
DK0885191T3 (da) | 1996-03-08 | 2002-05-06 | Medeva Europ Ltd | Opspaltning af threo-methylphenidat |
GB9606417D0 (en) | 1996-03-27 | 1996-06-05 | Chiroscience Ltd | Asymmetric cyclisation |
ATE321529T1 (de) | 1996-09-30 | 2006-04-15 | Alza Corp | Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung |
US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
CN1182839C (zh) | 1996-11-25 | 2005-01-05 | 阿尔萨公司 | 递增剂量的剂型 |
EP1782798A3 (en) | 1996-11-25 | 2008-05-21 | Alza Corporation | Ascending-dose dosage form |
CZ206299A3 (cs) | 1996-12-13 | 1999-09-15 | Medeva Europe Limited | Způsob přípravy enantiomerně obohaceného THREO-metalfenidátu |
GB9700912D0 (en) | 1997-01-17 | 1997-03-05 | Chiroscience Ltd | Resolution |
US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
CA2346001C (en) * | 1998-10-01 | 2003-12-30 | Elan Pharma International, Limited | Controlled release nanoparticulate compositions |
US6322819B1 (en) * | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
SK287674B6 (sk) | 1998-11-02 | 2011-05-06 | Elan Pharma International Limited | Mnohočasticový prostriedok s modifikovaným uvoľňovaním obsahujúci metylfenidát, pevná orálne dávková forma s jeho obsahom a jeho použitie |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US6384020B1 (en) | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
US6500459B1 (en) | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
GB9918735D0 (en) * | 1999-08-09 | 1999-10-13 | Straken Limited | Transdermal patches |
US6898455B2 (en) | 1999-10-29 | 2005-05-24 | The Mclean Hospital Corporation | Method for providing optimal drug dosage |
US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
US6569456B2 (en) | 2000-01-13 | 2003-05-27 | Osmotica Corp. | Osmotic device containing diltiazem and an ACE inhibitor or diuretic |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US6520921B1 (en) | 2000-06-20 | 2003-02-18 | Eastman Kodak Company | Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication |
US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
US20030232890A1 (en) | 2000-11-01 | 2003-12-18 | Sention, Inc. | Methods for treating an impairment in memory consolidation |
US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
US20040137062A1 (en) | 2001-05-25 | 2004-07-15 | Sham Chopra | Chronotherapy tablet and methods related thereto |
US7195778B2 (en) | 2001-07-10 | 2007-03-27 | Teva Pharmaceutical Industries Ltd. | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
US7157103B2 (en) | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
US6811794B2 (en) | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US6726624B2 (en) | 2002-03-06 | 2004-04-27 | The Mclean Hospital Corporation | Method and apparatus for determining attention deficit hyperactivity disorder (adhd) medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
EP1545476A4 (en) | 2002-09-09 | 2008-01-09 | Biovail Lab Int Srl | CHRONOTHERAPEUTIC DILTIAZEM PREPARATIONS AND THEIR ADMINISTRATION |
US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
US7910128B2 (en) | 2003-01-03 | 2011-03-22 | Supernus Pharmaceuticals, Inc. | Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics |
PT1644019E (pt) | 2003-05-29 | 2012-05-23 | Shire Llc | Compostos de anfetamina resistentes ao abuso |
US20050031688A1 (en) | 2003-08-04 | 2005-02-10 | Ayala William J. | Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
WO2005073222A1 (en) | 2004-01-29 | 2005-08-11 | Pfizer Japan, Inc. | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity |
ES2261006B1 (es) * | 2004-06-10 | 2007-11-01 | Laboratorios Rubio, S.A. | Pellet multicapa de liberacion controlada de metilfenidato. |
WO2006081518A2 (en) | 2005-01-28 | 2006-08-03 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
FR2892937B1 (fr) * | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
ES2627127T3 (es) * | 2006-05-09 | 2017-07-26 | Mallinckrodt Llc | Formas de dosificación sólidas de liberación modificada de orden cero |
AU2006343596A1 (en) * | 2006-05-12 | 2007-11-22 | Shire Llc | Controlled dose drug delivery system |
US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
FR2901478B1 (fr) * | 2006-05-24 | 2015-06-05 | Flamel Tech Sa | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee |
CN1985810A (zh) * | 2006-07-28 | 2007-06-27 | 中国人民解放军第二军医大学 | 盐酸哌甲酯缓控释胶囊及其制备方法 |
KR100888131B1 (ko) | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
EP2086519B1 (en) | 2006-10-30 | 2017-06-21 | HanAll Biopharma Co., Ltd. | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors |
CN103316326B (zh) | 2007-04-04 | 2016-06-15 | 希格默伊德药业有限公司 | 环孢菌素药物组合物 |
US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
AU2009207796B2 (en) * | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
CA2627198A1 (en) | 2008-03-27 | 2009-09-27 | Pharmascience Inc. | Methylphenidate extended release therapeutic drug delivery system |
AU2010300641B2 (en) | 2009-09-30 | 2016-03-17 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
-
2012
- 2012-03-23 PT PT171870231T patent/PT3272342T/pt unknown
- 2012-03-23 DK DK12760068.2T patent/DK2688557T3/da active
- 2012-03-23 SG SG2013071279A patent/SG193587A1/en unknown
- 2012-03-23 CA CA2830788A patent/CA2830788C/en active Active
- 2012-03-23 EP EP12760068.2A patent/EP2688557B1/en active Active
- 2012-03-23 SG SG10201901167SA patent/SG10201901167SA/en unknown
- 2012-03-23 MX MX2013010920A patent/MX357551B/es active IP Right Grant
- 2012-03-23 ES ES12760068.2T patent/ES2644942T3/es active Active
- 2012-03-23 EP EP21174219.2A patent/EP4011364B1/en active Active
- 2012-03-23 PT PT211742192T patent/PT4011364T/pt unknown
- 2012-03-23 PT PT127600682T patent/PT2688557T/pt unknown
- 2012-03-23 BR BR112013024401-1A patent/BR112013024401B1/pt active IP Right Grant
- 2012-03-23 JP JP2014501292A patent/JP6043785B2/ja active Active
- 2012-03-23 DK DK21174219.2T patent/DK4011364T3/da active
- 2012-03-23 AU AU2012230733A patent/AU2012230733B2/en active Active
- 2012-03-23 DK DK17187023.1T patent/DK3272342T3/da active
- 2012-03-23 EP EP23215283.5A patent/EP4316488A3/en active Pending
- 2012-03-23 CN CN201910483969.1A patent/CN110151731A/zh active Pending
- 2012-03-23 EP EP17187023.1A patent/EP3272342B1/en active Active
- 2012-03-23 CN CN201280024451.8A patent/CN103608004A/zh active Pending
- 2012-03-23 WO PCT/US2012/030472 patent/WO2012129551A1/en active Application Filing
- 2012-03-23 KR KR1020137027522A patent/KR101834033B1/ko active IP Right Grant
- 2012-03-23 ES ES21174219T patent/ES2973539T3/es active Active
- 2012-03-23 ES ES17187023T patent/ES2883589T3/es active Active
- 2012-03-23 US US13/429,292 patent/US9028868B2/en active Active
- 2012-03-23 KR KR1020167032196A patent/KR20160135373A/ko not_active Application Discontinuation
- 2012-03-23 MX MX2021000431A patent/MX2021000431A/es unknown
-
2013
- 2013-09-23 MX MX2022013590A patent/MX2022013590A/es unknown
- 2013-10-15 ZA ZA2013/07649A patent/ZA201307649B/en unknown
-
2016
- 2016-03-23 JP JP2016058474A patent/JP2016117767A/ja not_active Withdrawn
- 2016-09-16 AU AU2016228307A patent/AU2016228307A1/en not_active Abandoned
-
2017
- 2017-05-01 JP JP2017091305A patent/JP6325148B2/ja active Active
-
2018
- 2018-03-21 AU AU2018202002A patent/AU2018202002B2/en active Active
- 2018-09-25 JP JP2018179001A patent/JP2018197276A/ja not_active Withdrawn
-
2020
- 2020-03-02 JP JP2020035076A patent/JP2020079322A/ja not_active Withdrawn
-
2022
- 2022-03-01 JP JP2022030878A patent/JP2022066315A/ja not_active Withdrawn
-
2023
- 2023-12-28 JP JP2023223409A patent/JP2024019726A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017128614A5 (ja) | ||
JP2017019858A5 (ja) | ||
JP2017537168A5 (ja) | ||
JP2012153724A5 (ja) | ||
US11903908B2 (en) | Methods of administering amantadine | |
FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
US20210220281A1 (en) | Oral pharmaceutical compositions of mesalazine | |
JP2016117767A5 (ja) | ||
JP2011509295A5 (ja) | ||
JP2014508812A5 (ja) | ||
US20220175679A1 (en) | Compositions of midodrine and methods of using the same | |
NZ586025A (en) | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate | |
HRP20211269T1 (hr) | Kompozicije prolijeka na bazi monometil fumarata | |
HUE035830T2 (en) | New combination | |
US20110033506A1 (en) | Combination dosage form of low-dose modafinil and low-dose sildenafil | |
WO2005055955B1 (en) | DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY | |
US11622938B2 (en) | Oral pharmaceutical compositions of nicotinamide | |
JP2021001190A (ja) | トリパルス放出型賦活薬製剤 | |
TWI508755B (zh) | 供三甲氧苄嗪(trimetazidine)延長釋放之醫藥組合物 | |
JP2015506980A5 (ja) | ||
US20200054659A1 (en) | Extended release capecitabine capsules | |
US11033508B2 (en) | Delayed sustained release pharmaceutical compositions | |
JP2013536832A (ja) | ミルナシプランの制御放出医薬組成物 | |
CN101596158B (zh) | 一种对乙酰氨基酚、伪麻黄碱和右美沙芬的复方缓释制剂 | |
NZ598486A (en) | Pharmaceutical compositions methods and kit for glucocorticoid replacement therapy |